These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38204397)

  • 1. Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation.
    Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Urosevic A; Lefebvre P; Pilon D; George DJ
    J Med Econ; 2024; 27(1):201-214. PubMed ID: 38204397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States.
    Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Lefebvre P; Pilon D; George D
    J Med Econ; 2024; 27(1):381-391. PubMed ID: 38420699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States.
    Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Lefebvre P; Pilon D; George DJ
    J Manag Care Spec Pharm; 2024 Jul; 30(7):684-697. PubMed ID: 38950154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims.
    Freedland SJ; Davis MR; Epstein AJ; Arondekar B; Ivanova JI
    Adv Ther; 2023 Oct; 40(10):4480-4492. PubMed ID: 37531024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
    Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
    J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data.
    Swami U; Aggarwal H; Zhou M; Jiang S; Kim J; Li W; Laliberté F; Emond B; Agarwal N
    Clin Genitourin Cancer; 2023 Oct; 21(5):517-529. PubMed ID: 37248148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Treatment Patterns and Costs in Patients with Prostate Cancer and Bone Metastases.
    Wen L; Yao J; Valderrama A
    J Manag Care Spec Pharm; 2019 Mar; 25(3-b Suppl):S1-S11. PubMed ID: 30827188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.
    Schultz NM; Flanders SC; Wilson S; Brown BA; Song Y; Yang H; Lechpammer S; Kassabian V
    Adv Ther; 2018 Oct; 35(10):1639-1655. PubMed ID: 30191463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost impact of disease progression to metastatic castration-sensitive prostate cancer.
    Trinh QD; Chaves LP; Feng Q; Zhu J; Sandin R; Abbott T
    J Manag Care Spec Pharm; 2022 May; 28(5):544-554. PubMed ID: 35471070
    [No Abstract]   [Full Text] [Related]  

  • 11. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
    Armstrong A; Bui C; Fitch K; Sawhney TG; Brown B; Flanders S; Balk M; Deangelis J; Chambers J
    Curr Med Res Opin; 2017 Jun; 33(6):1133-1139. PubMed ID: 28318331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data.
    Freedland SJ; Ke X; Lafeuille MH; Romdhani H; Kinkead F; Lefebvre P; Petrilla A; Pulungan Z; Kim S; D'Andrea DM; Francis P; Ryan CJ
    Curr Med Res Opin; 2021 Apr; 37(4):609-622. PubMed ID: 33476184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population.
    Freedland SJ; Davis M; Epstein AJ; Arondekar B; Ivanova JI
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):327-333. PubMed ID: 37783836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
    Bui CN; O'Day K; Flanders S; Oestreicher N; Francis P; Posta L; Popelar B; Tang H; Balk M
    J Manag Care Spec Pharm; 2016 Feb; 22(2):163-70. PubMed ID: 27015255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug costs in the management of metastatic castration-resistant prostate cancer in Canada.
    Dragomir A; Dinea D; Vanhuyse M; Cury FL; Aprikian AG
    BMC Health Serv Res; 2014 Jun; 14():252. PubMed ID: 24927758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare resource use in advanced prostate cancer patients treated with docetaxel.
    Mehra M; Wu Y; Dhawan R
    J Med Econ; 2012; 15(5):836-43. PubMed ID: 22463616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data.
    Flaig TW; Potluri RC; Ng Y; Todd MB; Mehra M
    Cancer Med; 2016 Feb; 5(2):182-91. PubMed ID: 26710718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data.
    Liu J; Near A; Chiarappa JA; Wada K; Tse J; Burudpakdee C; Behl A; Ranganath R; Antonarakis ES
    J Med Econ; 2019 Oct; 22(10):1080-1087. PubMed ID: 31352849
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer in Chinese tertiary care hospital settings.
    Qian Z; Wang Y; Tang Z; Ren D; Wang Z; Chen W; Li Z
    J Med Econ; 2019 Aug; 22(8):728-735. PubMed ID: 30913930
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting.
    Freedland SJ; Hong A; El-Chaar N; Murty S; Ramaswamy K; Coutinho AD; Nimke D; Morgans AK
    Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):523-530. PubMed ID: 36517634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.